Temporary Change in PDL Status for the Neuropathic Pain Drug Class Effective April 3

March 31, 2023

Effective April 3, 2023, the Texas Health and Human Services Commission (HHSC) has temporarily removed the non-preferred status from the generic product lidocaine 5% patch on the preferred drug list (PDL). (The lidocaine patch 5% is in the neuropathic pain drug class.) This temporary removal is in response to the shortage of the preferred brand name product Lidoderm 5% patch, which was discontinued by the manufacturer.

Note: The preferred status of the brand name product Lidoderm (NDC 63481-0687-06) will not change so that any available existing stock can be used.

Effective April 3, 2023, the following generic drugs are affected:

NDC Generic Drug Name
00378905593 Lidocaine 5% patch
00591352530 Lidocaine 5% patch
00603188016 Lidocaine 5% patch
16714017730 Lidocaine 5% patch
42858011830 Lidocaine 5% patch
65162079108 Lidocaine 5% patch

These changes allow providers to prescribe the generic lidocaine patches without a PDL prior authorization and continue accessing necessary medication for clients. This is a temporary change until HHSC can further assess the availability of any alternative brand name products in the neuropathic pain PDL class. HHSC will provide more information about future PDL status changes when it becomes available.